The nitrogen-containing bisphosphonate, zoledronic acid, increases mineralisation of human bone-derived cells in vitro.

Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One (2008) 1.60

Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone (2010) 1.41

Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J (2010) 1.05

Beyond gap junctions: Connexin43 and bone cell signaling. Bone (2012) 1.02

Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int (2008) 0.98

Enhancement of periprosthetic bone quality with topical hydroxyapatite-bisphosphonate composite. J Bone Joint Surg Am (2008) 0.89

Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87

Pharmacological management of osteogenesis. Clinics (Sao Paulo) (2014) 0.85

Role of connexin 43 in the mechanism of action of alendronate: dissociation of anti-apoptotic and proliferative signaling pathways. Arch Biochem Biophys (2012) 0.84

Controlled delivery of zoledronate improved bone formation locally in vivo. PLoS One (2014) 0.81

Zoledronate reduces unwanted bone resorption in intercalary bone allografts. Int Orthop (2009) 0.81

Bisphosphonates induce the osteogenic gene expression in co-cultured human endothelial and mesenchymal stem cells. J Cell Mol Med (2013) 0.80

Surface immobilized zoledronate improves screw fixation in rat bone: a new method for the coating of metal implants. J Mater Sci Mater Med (2010) 0.79

Zoledronic acid at subtoxic dose extends osteoblastic stage span of primary human osteoblasts. Clin Oral Investig (2014) 0.76

Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells. Acta Orthop (2016) 0.75

Zoledronic acid suppresses transforming growth factor-β-induced fibrogenesis by human gingival fibroblasts. Int J Mol Med (2016) 0.75

Zoledrinic Acid Induces Steoblastic Differentiation of Mesenchymal Stem Cells without Change in Hypomethylation Status of OSTERIX Promoter. Cell J (2012) 0.75

Prolonged alendronate treatment prevents the decline in serum TGF-β1 levels and reduces cortical bone strength in long-term estrogen deficiency rat model. Bone (2012) 0.75

Does pamidronate enhance the osteogenesis in mesenchymal stem cells derived from fibrous hamartoma in congenital pseudarthrosis of the tibia? Bone Rep (2016) 0.75

Functional impact of global rare copy number variation in autism spectrum disorders. Nature (2010) 14.66

Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05

Investigation of multipotent postnatal stem cells from human periodontal ligament. Lancet (2004) 7.84

SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci U S A (2003) 6.80

Perivascular niche of postnatal mesenchymal stem cells in human bone marrow and dental pulp. J Bone Miner Res (2003) 5.23

Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci (2003) 4.10

Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 3.61

A genome-wide scan for common alleles affecting risk for autism. Hum Mol Genet (2010) 3.42

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood (2008) 2.80

Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res (2003) 2.73

Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol (2002) 2.61

miRNA-mediated deadenylation is orchestrated by GW182 through two conserved motifs that interact with CCR4-NOT. Nat Struct Mol Biol (2011) 2.61

A new social communication intervention for children with autism: pilot randomised controlled treatment study suggesting effectiveness. J Child Psychol Psychiatry (2004) 2.59

A global perspective on trends in nature-based tourism. PLoS Biol (2009) 2.58

EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage specification. Stem Cells (2014) 2.53

Individual common variants exert weak effects on the risk for autism spectrum disorderspi. Hum Mol Genet (2012) 2.46

Adult human dental pulp stem cells differentiate toward functionally active neurons under appropriate environmental cues. Stem Cells (2008) 2.42

Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells (2008) 2.39

Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood (2010) 2.37

OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood (2006) 2.29

Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2. J Bone Miner Res (2013) 2.25

A-317491, a novel potent and selective non-nucleotide antagonist of P2X3 and P2X2/3 receptors, reduces chronic inflammatory and neuropathic pain in the rat. Proc Natl Acad Sci U S A (2002) 2.24

Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. Blood (2005) 2.13

Bril: a novel bone-specific modulator of mineralization. J Bone Miner Res (2008) 2.11

Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One (2011) 2.10

The therapeutic applications of multipotential mesenchymal/stromal stem cells in skeletal tissue repair. J Cell Physiol (2009) 2.00

Periodontal ligament stem cell-mediated treatment for periodontitis in miniature swine. Stem Cells (2008) 1.99

A novel monoclonal antibody (STRO-3) identifies an isoform of tissue nonspecific alkaline phosphatase expressed by multipotent bone marrow stromal stem cells. Stem Cells Dev (2007) 1.96

Barriers and facilitators to primary care or human immunodeficiency virus clinics providing methadone or buprenorphine for the management of opioid dependence. Arch Intern Med (2005) 1.86

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res (2003) 1.82

Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood (2005) 1.80

A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest (2004) 1.71

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood (2007) 1.70

Diversity of noroviruses cocirculating in the north of England from 1998 to 2001. J Clin Microbiol (2004) 1.65

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood (2008) 1.64

Vitamin K promotes mineralization, osteoblast-to-osteocyte transition, and an anticatabolic phenotype by {gamma}-carboxylation-dependent and -independent mechanisms. Am J Physiol Cell Physiol (2009) 1.64

Pharmacologic stem cell based intervention as a new approach to osteoporosis treatment in rodents. PLoS One (2008) 1.60

Immunomodulatory properties of human periodontal ligament stem cells. J Cell Physiol (2009) 1.59

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood (2004) 1.57

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst (2007) 1.56

The conceptualization and measurement of therapeutic alliance: an empirical review. Clin Psychol Rev (2008) 1.56

Evolutionary dynamics of local pandemic H1N1/2009 influenza virus lineages revealed by whole-genome analysis. J Virol (2011) 1.55

Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone (2007) 1.52

BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res (2007) 1.50

Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care (2014) 1.48

Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther (2007) 1.47

TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment. Stem Cells (2009) 1.47

Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol (2012) 1.47

RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res (2003) 1.46

A novel approach of homozygous haplotype sharing identifies candidate genes in autism spectrum disorder. Hum Genet (2011) 1.43

Immunomodulatory properties of stem cells from human exfoliated deciduous teeth. Stem Cell Res Ther (2010) 1.43

Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res (2005) 1.40

TWEAK is a novel arthritogenic mediator. J Immunol (2006) 1.37

Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36

High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res (2011) 1.34

RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res (2006) 1.33

Stem cells and periodontal regeneration. Periodontol 2000 (2006) 1.33

Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther (2007) 1.32

Public health value of next-generation DNA sequencing of enterohemorrhagic Escherichia coli isolates from an outbreak. J Clin Microbiol (2012) 1.31

Evolutionary pathways of the pandemic influenza A (H1N1) 2009 in the UK. PLoS One (2011) 1.31

Long-term imatinib therapy promotes bone formation in CML patients. Blood (2007) 1.30

Analgesic profile of intrathecal P2X(3) antisense oligonucleotide treatment in chronic inflammatory and neuropathic pain states in rats. Pain (2002) 1.27

Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget (2011) 1.27

Quality of interaction between at-risk infants and caregiver at 12-15 months is associated with 3-year autism outcome. J Child Psychol Psychiatry (2012) 1.27

Dysregulation of bone remodeling by imatinib mesylate. Blood (2009) 1.26

Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis (2002) 1.26

Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol (2005) 1.26

Implanted adult human dental pulp stem cells induce endogenous axon guidance. Stem Cells (2009) 1.24

Parent-infant interaction in infant siblings at risk of autism. Res Dev Disabil (2012) 1.22

Lysophosphatidic acid receptors 1 and 2 play roles in regulation of vascular injury responses but not blood pressure. Circ Res (2008) 1.20

Genomic profiling of mesenchymal stem cells. Stem Cell Rev (2009) 1.20

Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism. J Bone Miner Res (2011) 1.19

Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res (2009) 1.18

Progression of acetabular periprosthetic osteolytic lesions measured with computed tomography. J Bone Joint Surg Am (2007) 1.16

A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res (2007) 1.15

Off-label recombinant factor VIIa use and thrombosis in children: a multi-center cohort study. J Pediatr (2010) 1.15

Characterisation and developmental potential of ovine bone marrow derived mesenchymal stem cells. J Cell Physiol (2009) 1.14